NCT06468605View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2030

Conditions

Recurrent or Progressive High-grade Glioma

Interventions

BIOLOGICAL

JCXH-211

JCXH-211 is a lipid nanoparticle (LNP) encapsulated srRNA, encoding the human IL-12 protein.

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT06468605 - Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma | Biotech Hunter | Biotech Hunter